Trending...
- Boston: SCHOOLS URGED TO REGISTER FOR THE BCYF SPELLING BEE
- Massachusetts: Governor Healey Announces Veterans Equality Review Board (VERB) to Support Veterans Discharged Under "Don't Ask, Don't Tell" Policy
- Sidow Sobrino Announces 12th Album, "Seminal"
Download
The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predictable ridge volume throughout the bone regeneration process. (Graphic: Business Wire)
LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.
More on Boston Chron
"We have optimized the TETRANITE bone adhesive technology to accelerate the substitution of the biomaterial with new bone through key engineering and manufacturing innovations which significantly increase the porosity of the material," said Rahul Jadia, PhD, RevBio's R&D Manager of Technology Development, who has led the development of this novel adhesive bone scaffold product. "This grant will allow the company to conduct a pivotal animal study necessary to demonstrate safety and efficacy of the product and to file an Investigational Device Exemption (IDE) application with the FDA next year to start a clinical trial."
Research shows that 44% of all patients who receive a dental implant have a missing tooth when they start treatment with varying degrees of bone loss depending on how long the tooth had been missing. These patients must undergo a ridge augmentation procedure in which various bone graft materials are placed using additional fixation and containment devices to protect the graft during the healing process. These procedures increase the width and height of the residual jawbone to replace atrophied bone so that a dental implant can be successfully placed. In over 30% of these cases, however, existing bone graft materials fail to achieve the desired clinical results, and another bone graft procedure must be conducted, increasing the overall time and cost of treatment. This product compliments RevBio's existing clinical program to treat the larger population of patients who need an immediate dental implant following tooth extraction.
This grant significantly enhances prior funding awarded to RevBio by the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center which is a research consortium funded by the National Institute of Dental and Cranial Research (U24-DE029462) to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice.
More on Boston Chron
"This enhanced adhesive formulation of TETRANITE resorbs and is replaced by bone on a timescale similar to existing graft materials but, unlike those existing materials, it does not require ancillary containment devices like membranes or meshes or fixation aids like tacks and screws," said Joseph P. Fiorellini, DMD, DMSc, Professor at the University of Pennsylvania School of Dental Medicine and Chair of RevBio's Dental Scientific Advisory Board. "The clinical use of this material will reduce the time and complexity of ridge augmentation procedures and likely lead to more consistent results with better volume maintenance of these grafts."
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called TETRANITE®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.
Contacts
Michael Tiedemann
mtiedemann@revbio.com
Release Summary
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
#Hashtags
Social Media Profiles
Contacts
Michael Tiedemann
mtiedemann@revbio.com
The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predictable ridge volume throughout the bone regeneration process. (Graphic: Business Wire)
- The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predictable ridge volume throughout the bone regeneration process. (Graphic: Business Wire)
LOWELL, Mass.--(BUSINESS WIRE)--RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development.
More on Boston Chron
- Bitsight Named an Overall Leader in 2023 KuppingerCole Leadership Compass Report for Attack Surface Management USA - English USA - English
- SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference
- Samuel Adams Just Unlocked Beer Lovers' Phobia: Cenosillicaphobia
- Jennifer Steffens, PE Joins Opti Software for Stormwater Solutions as Vice President of Marketing
- Massachusetts Selected to Host ARPA-H Hub as Part of Nationwide Health Innovation Network
"We have optimized the TETRANITE bone adhesive technology to accelerate the substitution of the biomaterial with new bone through key engineering and manufacturing innovations which significantly increase the porosity of the material," said Rahul Jadia, PhD, RevBio's R&D Manager of Technology Development, who has led the development of this novel adhesive bone scaffold product. "This grant will allow the company to conduct a pivotal animal study necessary to demonstrate safety and efficacy of the product and to file an Investigational Device Exemption (IDE) application with the FDA next year to start a clinical trial."
Research shows that 44% of all patients who receive a dental implant have a missing tooth when they start treatment with varying degrees of bone loss depending on how long the tooth had been missing. These patients must undergo a ridge augmentation procedure in which various bone graft materials are placed using additional fixation and containment devices to protect the graft during the healing process. These procedures increase the width and height of the residual jawbone to replace atrophied bone so that a dental implant can be successfully placed. In over 30% of these cases, however, existing bone graft materials fail to achieve the desired clinical results, and another bone graft procedure must be conducted, increasing the overall time and cost of treatment. This product compliments RevBio's existing clinical program to treat the larger population of patients who need an immediate dental implant following tooth extraction.
This grant significantly enhances prior funding awarded to RevBio by the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center which is a research consortium funded by the National Institute of Dental and Cranial Research (U24-DE029462) to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice.
More on Boston Chron
- Boston: Affordable Homeownership Opportunity in Dorchester
- Boston: Latest Updates from the Mayor's Office of Housing: September 22, 2023
- Massachusetts: Governor Healey Creates Commission to Accelerate Siting and Permitting of Clean Energy Infrastructure
- The Luxe Team at Dale Sorensen Real Estate Brevard Presents 100 Ocean Condominium in Melbourne, Florida
- Boston and Providence Wendy's Celebrate National Coffee Day with Free Coffee ALL WEEK LONG
"This enhanced adhesive formulation of TETRANITE resorbs and is replaced by bone on a timescale similar to existing graft materials but, unlike those existing materials, it does not require ancillary containment devices like membranes or meshes or fixation aids like tacks and screws," said Joseph P. Fiorellini, DMD, DMSc, Professor at the University of Pennsylvania School of Dental Medicine and Chair of RevBio's Dental Scientific Advisory Board. "The clinical use of this material will reduce the time and complexity of ridge augmentation procedures and likely lead to more consistent results with better volume maintenance of these grafts."
About RevBio, Inc.
RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called TETRANITE®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.
Contacts
Michael Tiedemann
mtiedemann@revbio.com
Release Summary
RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
#Hashtags
- #TETRANITE (https://twitter.com/hashtag/TETRANITE?src=hash)
- #DentalBoneGrafting (https://twitter.com/hashtag/DentalBoneGrafting?src=hash)
- #BoneScaffold (https://twitter.com/hashtag/BoneScaffold?src=hash)
- #clinicalstage (https://twitter.com/hashtag/clinicalstage?src=hash)
- #regeneration (https://twitter.com/hashtag/regeneration?src=hash)
- #investment (https://twitter.com/hashtag/investment?src=hash)
- #biomaterials (https://twitter.com/hashtag/biomaterials?src=hash)
- #dental (https://twitter.com/hashtag/dental?src=hash)
- #BoneAdhesive (https://twitter.com/hashtag/BoneAdhesive?src=hash)
- #innovation (https://twitter.com/hashtag/innovation?src=hash)
Social Media Profiles
- RevBio on Facebook (https://www.facebook.com/REVBIOINC/)
- RevBio on Twitter (https://twitter.com/revbio_?lang=en)
- RevBio on LinkedIn (https://www.linkedin.com/company/revbio-inc/)
- RevBio on Instagram (https://www.instagram.com/revbio_/?hl=en)
- RevBio on Vimeo (https://vimeo.com/revbio)
Contacts
Michael Tiedemann
mtiedemann@revbio.com
Filed Under: Business
0 Comments
Latest on Boston Chron
- Museum of Science, Boston and Big Sister Association of Greater Boston Partner to Bring Free Museum Admission to Girls and Mentors
- Boston: Affordable Homeownership Opportunity in Roxbury
- HubSpot Named a Leader in the 2023 Gartner® Magic Quadrant™ for B2B Marketing Automation Platforms for the Third Consecutive Year
- New Study Finds Wide Disparities in Bicycle Safety Across U.S. Cities
- Free Archery Classes for Adults and Teens in Boston
- Boston: Mayor Michelle Wu Appoints Mary Skelton Roberts to the MBTA Board of Directors
- Gaslight Studios Announces Acceptance Into Maestro Management Consulting Consortium
- Wellsboro, Pennsylvania Named Ninth Best Fall Town in the U.S. for Foliage
- Actionstep Acquires North American Legal Accounting Platform Soluno
- Boston: October is Italian-American Heritage Month
- RelyMD Bolsters its Telehealth Platform with Mental Health Services via CuraLinc Partnership
- Announcing INVIDICUM, the latest novel by Michael Brodsky
- Live Good Inc. Celebrates Diversity and Unity: A Beacon of Progress in the Spirit of Crissy Field, Angel Island and the Buffalo Soldiers
- Knobull Makes Sure That Job Seekers Stand Out In The Crowded Market
- AMERICAST Provides PreCast Pads to Charge Stations
- Boston Area Oom Yung Doe Martial Arts Schools Host the Master Level Teaching Team
- Massachusetts: Governor Healey Orders Statewide Maternal Health Review to Ensure Equitable Care in All Communities
- Massachusetts: Healey-Driscoll Administration Secures More Than $108 Million for Train Corridor Improvements Between Springfield and Worcester
- Sheila Stubbs Taylor of Detroit music royalty is "Chasing" on new single
- Sidow Sobrino Announces 12th Album, "Seminal"